Arvinas, Inc. (ARVN) vs ProKidney Corp. (PROK)

Arvinas, Inc. and ProKidney Corp. are both Biotechnology companies. Arvinas, Inc. and ProKidney Corp. are of similar size ($514.0M and $509.4M). ProKidney Corp. has negative trailing earnings, so its P/E is not meaningful; Arvinas, Inc. trades at 58.3×. Arvinas, Inc. has the higher net margin (2.94% vs −10,288.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Arvinas, Inc. leads on 9 and ProKidney Corp. on 5.

Valuation

Metric ARVN PROK Biotechnology median
P/E 58.31 n/m 7.88
P/S 1.55 364.91 11.47
P/B 0.87 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 4.20 n/m 0.74
EV/Sales (0.24) 143.78 10.73
Earnings yield 1.72% (34.38%) (28.84%)
Free cash flow yield (42.51%) (47.41%) (23.03%)

Profitability

Metric ARVN PROK Biotechnology median
Gross margin 97.16% 100.00% 65.16%
Operating margin (5.72%) (21,664.55%) 0.00%
Net margin 2.94% (10,288.39%) 0.00%
Free cash flow margin (65.93%) (17,300.61%) 0.00%
Return on equity 1.59% 8.92% (57.72%)
Return on assets 1.17% (27.10%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARVN PROK Biotechnology median
Revenue growth (TTM) (15.05%) — 5.64%
EPS growth (last fiscal year) 58.84% 16.13% —
Revenue growth, 5-year CAGR 58.93% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARVN PROK Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.91 8.36 4.73
Net debt to EBITDA 5.62 1.70 0.96

Dividend

Metric ARVN PROK Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ARVN PROK Biotechnology median
Market cap 509.36m 513.95m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack